Page last updated: 2024-10-26

doxapram and Neoplasms

doxapram has been researched along with Neoplasms in 1 studies

Doxapram: A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)
doxapram : A member of the class of pyrrolidin-2-ones that is N-ethylpyrrolidin-2-one in which both of the hydrogens at the 3 position (adjacent to the carbonyl group) are substituted by phenyl groups, and one of the hydrogens at the 4 position is substituted by a 2-(morpholin-4-yl)ethyl group. A central and respiratory stimulant with a brief duration of action, it is used (generally as the hydrochloride or the hydrochloride hydrate) as a temporary treatment of acute respiratory failure, particularly when superimposed on chronic obstructive pulmonary disease, and of postoperative respiratory depression. It has also been used for treatment of postoperative shivering.

Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Li, E1
Sritharan, G1
Mogos, M1
Roffey, P1
Thangathurai, D1

Other Studies

1 other study available for doxapram and Neoplasms

ArticleYear
Doxapram revisited in patients with cancer.
    Journal of palliative medicine, 2009, Volume: 12, Issue:8

    Topics: Doxapram; Humans; Neoplasms; Respiratory System Agents; Terminally Ill

2009